Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision updated from v3.7.0 to v3.7.1; the study page remains an error page.
    Difference
    0.2%
    Check dated 2026-10-09T11:24:15.000Z thumbnail image
  2. Check
    18 days ago
    No Change Detected
  3. Check
    25 days ago
    Change Detected
    Summary
    The study record page now renders a 403 Forbidden error instead of the full study details. The page displays a minimal header with a Home link, indicating the content is currently inaccessible due to access restrictions.
    Difference
    22%
    Check dated 2026-09-25T13:26:20.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    UI label capitalization for the contact information was adjusted. A new Revision: v3.7.0 marker was added, and several related topics entries (including Melanoma and MedlinePlus Genetics) were removed.
    Difference
    0.2%
    Check dated 2026-09-18T12:32:35.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, indicating a small update to the page's version history.
    Difference
    0.0%
    Check dated 2026-08-28T11:44:41.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Eligibility criteria text was refined by updating the ANC and bilirubin thresholds (removing and rewording prior criteria). A MedlinePlus Genetics reference was added under related topics to provide melanoma-related background information.
    Difference
    0.5%
    Check dated 2026-08-21T10:54:53.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Melanoma, the related topics header, and MedlinePlus Genetics were removed from the page's related topics section, reducing the topic labels shown with the study.
    Difference
    0.1%
    Check dated 2026-08-14T11:15:38.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.